These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 33371100)
1. Effects of tumor origins and therapeutic options on the prognosis of hepatic neuroendocrine tumors: A retrospective study. Jiao X; Luan W; Peng X; Liu L; Zhang L; Zhou L Medicine (Baltimore); 2020 Dec; 99(51):e23655. PubMed ID: 33371100 [TBL] [Abstract][Full Text] [Related]
2. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852 [TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Tumors of Unknown Primary in the Setting of Cytoreductive Hepatectomy. Ammann M; Gudmundsdottir H; Hackl H; Antwi SKA; Santol J; Habermann EB; Thiels CA; Warner SG; Truty MJ; Kendrick ML; Smoot RL; Nagorney DM; Cleary SP; Halfdanarson TR; Starlinger PP Ann Surg Oncol; 2024 Aug; 31(8):4931-4941. PubMed ID: 38717544 [TBL] [Abstract][Full Text] [Related]
4. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection. Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559 [TBL] [Abstract][Full Text] [Related]
5. Ki-67 Labeling Index Variability Between Surgically Resected Primary and Metastatic Hepatic Lesions of Gastroenteropancreatic Neuroendocrine Neoplasms. Furukawa T; Ozaka M; Takamatsu M; Takazawa Y; Inamura K; Inoue Y; Mie T; Takeda T; Kanata R; Kasuga A; Matsuyama M; Sasaki T; Takahashi Y; Sasahira N Int J Surg Pathol; 2021 Aug; 29(5):475-481. PubMed ID: 33543658 [No Abstract] [Full Text] [Related]
6. Hepatic surgery for metastases from neuroendocrine tumors. Sarmiento JM; Que FG Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141 [TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification. Burad DK; Kodiatte TA; Rajeeb SM; Goel A; Eapen CE; Ramakrishna B World J Gastroenterol; 2016 Oct; 22(40):8956-8966. PubMed ID: 27833387 [TBL] [Abstract][Full Text] [Related]
8. Comparative Clinical Analysis of Gastroenteropancreatic Neuroendocrine Carcinomas with Liver Metastasis and Primary Hepatic Neuroendocrine Carcinomas. Qiu MJ; Chen YB; Bi NR; Yang SL; He XX; Xiong ZF Dis Markers; 2018; 2018():9191639. PubMed ID: 30416612 [TBL] [Abstract][Full Text] [Related]
9. Hepatic neuroendocrine tumors: gadoxetic acid-enhanced magnetic resonance imaging findings with an emphasis on differentiation between primary and secondary tumors. Cha DI; Kang TW; Jang KM; Kim YK; Kim SH; Ha SY; Sohn I Abdom Radiol (NY); 2018 Dec; 43(12):3331-3339. PubMed ID: 29858937 [TBL] [Abstract][Full Text] [Related]
10. Clinical analysis of gastroenteropancreatic neuroendocrine tumor with liver metastasis, compared with primary hepatic neuroendocrine tumor. Shen YH; Chen S; Zhang WT; Ji Y; Yu L; Sun HC; Qiu SJ; Ren N; Zhou J J Cancer Res Ther; 2014 Dec; 10 Suppl():276-80. PubMed ID: 25693935 [TBL] [Abstract][Full Text] [Related]
11. Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors. Du S; Ni J; Weng L; Ma F; Li S; Wang W; Sang X; Lu X; Zhong S; Mao Y Medicine (Baltimore); 2015 Aug; 94(34):e1429. PubMed ID: 26313798 [TBL] [Abstract][Full Text] [Related]
12. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target. Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545 [TBL] [Abstract][Full Text] [Related]
13. Treatment of liver metastases in patients with digestive neuroendocrine tumors. Rossi RE; Massironi S; Spampatti MP; Conte D; Ciafardini C; Cavalcoli F; Peracchi M J Gastrointest Surg; 2012 Oct; 16(10):1981-92. PubMed ID: 22829240 [TBL] [Abstract][Full Text] [Related]
14. Management of patients with hepatic metastases from neuroendocrine tumors. Clift AK; Frilling A Ann Saudi Med; 2014; 34(4):279-90. PubMed ID: 25811199 [TBL] [Abstract][Full Text] [Related]
15. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver. Keutgen XM; Schadde E; Pommier RF; Halfdanarson TR; Howe JR; Kebebew E Semin Oncol; 2018 Aug; 45(4):232-235. PubMed ID: 30318110 [TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine liver metastases: Value of apparent diffusion coefficient and enhancement ratios for characterization of histopathologic grade. Besa C; Ward S; Cui Y; Jajamovich G; Kim M; Taouli B J Magn Reson Imaging; 2016 Dec; 44(6):1432-1441. PubMed ID: 27227756 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study. Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205 [TBL] [Abstract][Full Text] [Related]
19. Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms: a novel therapeutic strategy. Maekawa A; Kudo A; Kishino M; Murase Y; Watanabe S; Ishikawa Y; Ueda H; Akahoshi K; Ogawa K; Ono H; Tanaka S; Kinowaki Y; Tanabe M J Cancer Res Clin Oncol; 2022 Mar; 148(3):697-706. PubMed ID: 33904982 [TBL] [Abstract][Full Text] [Related]